FindTrial
Sign In

molecular target therapy

2 trials

Sponsors

Yamamoto Noboru, Arakawa Ayumu

Conditions

Pediatric and AYA solid tumor patients aged 0-29 years with no standard treatment or refractory/into Solid Tumors in Children and AYAsSolid Tumor solid tumor

Phase 1

NCCH2220 trial
RecruitingJPRN-jRCTs031230544
Arakawa AyumuPediatric and AYA solid tumor patients aged 0-29 years with no standard treatment or refractory/into Solid Tumors in Children and AYAs
Start: 2024-01-23Target: 100Updated: 2026-06-29

Phase 2

The prospective trial of patient-proposed healthcare services with multiple targeted agent based on gene profiling.
RecruitingJPRN-jRCTs031190104
Yamamoto NoboruSolid Tumor solid tumor
Start: 2019-10-03Target: 1000Updated: 2026-06-29

Related Papers

Capmatinib for High-Level MET-Amplified Metastatic Gastric Cancer Identified by Comprehensive Genomic Profiling: A Case Report and Literature Review.
2026-08-07
Metastatic Testicular Germ Cell Tumor in a Patient With Neurofibromatosis Type 1: Treatment With Trametinib Based on <i>NF1</i> Gene Mutation.
2026-07-09
Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort.
2026-07-06
Efficacy of pazopanib for a patient with FGFR1-amplified breast cancer : a case report
Case Reports in Oncology2026-05-29
A Case of Metastatic Castration‐Resistant Prostate Cancer With <i>RAD54L</i> Mutation Responding to Niraparib
IJU Case Reports2025-09-29
Phase II trial of trametinib in patients with advanced solid tumors harboring genomic alterations in the MAPK pathway: Results from the BELIEVE trial (NCCH1901).
Journal of Clinical Oncology2025-05-28
A Case of Metastatic Castration-resistant Prostate Cancer with Tumor Mutation Burden-high Presented Remarkable Response to Atezolizumab
Journal of Precision Oncology2024-11-28
A multicohort platform trial to improve drug access for pediatric cancer patients in Japan: The PARTNER trial (NCCH2220).
Journal of Clinical Oncology2024-06-01
Dabrafenib and trametinib administration in patients with <i>BRAF</i> V600E/R or non-V600 <i>BRAF</i> mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial.
2024-02-0220 citations
Phase II trial of dabrafenib and trametinib in patients with BRAFV600E/R or non-BRAFV600 mutated advanced solid tumors: Results from the BELIEVE trial (NCCH1901).
Journal of Clinical Oncology2023-06-011 citations
Progress report of a cross-organ and biomarker-based platform study: BELIEVE trial NCCH1901.
Journal of Clinical Oncology2023-06-011 citations